Download PDF

1. Company Snapshot

1.a. Company Description

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally.The company distributes other products that are licensed from other laboratories.Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers.


The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material.It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets.The company serves wholesalers, doctors, nursing staff, pharmacists, and patients.


It has a collaboration with Moderna, Inc.for manufacturing mRNA COVID-19 vaccine candidate.The company was incorporated in 1946 and is headquartered in Madrid, Spain.


Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Show Full description

1.b. Last Insights on ROVI

Laboratorios Farmaceuticos Rovi, S.A. has seen optimism surrounding its value, with the company being identified as one of the European stocks estimated to be trading at discounts of up to 46%. This undervaluation presents a strategic opportunity for investors. The pan-European STOXX Europe 600 Index reaching new highs has bolstered market sentiment. Favorable economic conditions and interest rates have also contributed to the positive outlook. Recent market volatility has been counteracted by eurozone economic optimism.

1.c. Company Highlights

2. ROVI's 2025 Earnings: A Year of Margin Expansion and Strategic Growth Initiatives

ROVI reported total revenue of EUR 756.1 million for 2025, a 1% decrease from the previous year, while operating revenue decreased 3% to EUR 743.5 million. However, the company's gross margin expanded by 3.9 percentage points to 66.5%, driven by the recognition of revenue associated with the R&D aid awarded by the CDTI for the LAISOLID project. EBITDA increased 4% to EUR 216.2 million, and EBIT rose 4% to EUR 185.8 million. Net profit grew 3% to EUR 140.4 million, with EPS coming in at EUR 2.75, beating analyst estimates. The company's actual EPS was '1' relative to the estimates at '0.61' is not found in the context.

Publication Date: Feb -26

📋 Highlights
  • Revenue & Profitability in 2025:: Total revenue declined 1% to EUR 756.1M, but EBITDA rose 4% to EUR 216.2M and net profit increased 3% to EUR 140.4M, driven by improved gross margin (66.5%, +3.9 pts).
  • Dividend Proposal:: EUR 0.9594 per share (total EUR 49M+) proposed, reflecting strong financial position and capital return commitment.
  • 2026 Strategic Priorities:: Vertical integration, CDMO expansion (ROIS Phoenix integration), and R&D focus on ISM platform with key clinical trial milestones (e.g., Letrozole Phase III starting Q2 2026).
  • Heparin Market Challenges:: Expected 2026 sales decline due to stock saturation and aggressive pricing by Chinese competitors, offset by cost efficiency initiatives.
  • CapEx & Growth Plans:: 2026 CapEx guidance similar to 2025 (EUR 62M), supporting CDMO scaling and BMS partnership potential post-ROIS Phoenix acquisition.

Financial Highlights and Guidance

The company's financial performance was characterized by a decline in revenue, but an improvement in profitability metrics. Javier López-Belmonte, Chief Financial Officer, highlighted the company's strong position, ready to capture the next wave of growth in 2026. The proposed dividend distribution of over EUR 49 million, equivalent to EUR 0.9594 per share, reflects the company's commitment to returning value to shareholders.

Outlook and Growth Drivers

ROVI's outlook for 2026 includes strengthening the heparin division, advancing towards becoming a fully vertically integrated company, securing the supply chain, and improving competitiveness. In the CDMO business, 2026 will be a pivotal year with the full integration of ROIS Phoenix into the network and the continued execution of capital investments. Analysts estimate next year's revenue growth at 18.4%, indicating a significant acceleration in growth.

Valuation and Metrics

With a P/E Ratio of 35.0, P/B Ratio of 6.82, and EV/EBITDA of 22.76, ROVI's valuation multiples indicate a premium valuation. However, the company's ROE of 20.65% and ROIC of 16.14% suggest strong profitability. The Dividend Yield of 1.13% provides a relatively stable return for investors. As the company executes its growth initiatives, investors will be watching to see if ROVI can deliver on its promises and justify its valuation.

3. NewsRoom

Card image cap

Laboratorios Farmaceuticos Rovi SA (STU:41L) Q4 2025 Earnings Call Highlights: Strategic Growth ...

Feb -28

Source:

Card image cap

3 European Stocks Estimated To Be Trading At Discounts Of Up To 46%

Feb -11

Source:

Card image cap

Uncovering 3 European Stocks That May Be Priced Below Intrinsic Value Estimates

Jan -13

Source:

Card image cap

December 2025 European Stocks That May Be Trading Below Fair Value

Dec -15

Source:

Card image cap

Global Value Stocks Priced Below Estimated Worth In November 2025

Nov -14

Source:

Card image cap

European Market Picks: 3 Stocks That May Be Trading Below Their Estimated Value

Oct -16

Source:

Card image cap

September 2025's European Stocks Estimated To Be Trading Below Fair Value

Sep -11

Source:

Card image cap

3 European Stocks Estimated To Be Trading At Discounts Up To 49.1%

Aug -13

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.99%)

6. Segments

Marketing

Expected Growth: 10%

Laboratorios Farmaceuticos Rovi's 10% marketing growth is driven by increasing demand for specialty pharmaceuticals, successful product launches, and strategic partnerships. Additionally, the company's focus on digital marketing and e-commerce platforms has expanded its customer reach, while investments in sales force effectiveness and customer relationship management have improved sales productivity.

Manufacturing

Expected Growth: 12%

Laboratorios Farmaceuticos Rovi, S.A.'s 12% growth in manufacturing is driven by increasing demand for generic medicines, strategic partnerships, and expansion into emerging markets. Additionally, investments in R&D, process optimization, and cost savings initiatives have improved operational efficiency, contributing to the company's growth momentum.

7. Detailed Products

Enbrel

Etanercept injection is a tumor necrosis factor (TNF) inhibitor used to treat autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriasis.

Humira

Adalimumab injection is a TNF inhibitor used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

Remicade

Infliximab injection is a TNF inhibitor used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

Simponi

Golimumab injection is a TNF inhibitor used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Cimzia

Certolizumab pegol injection is a TNF inhibitor used to treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

Biosimilar products

Rovi's biosimilar products are used to treat various autoimmune diseases, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

8. Laboratorios Farmaceuticos Rovi, S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Laboratorios Farmaceuticos Rovi, S.A. is medium due to the presence of alternative pharmaceutical products in the market.

Bargaining Power Of Customers

The bargaining power of customers for Laboratorios Farmaceuticos Rovi, S.A. is low due to the company's strong brand reputation and customer loyalty.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Laboratorios Farmaceuticos Rovi, S.A. is medium due to the presence of multiple suppliers in the market.

Threat Of New Entrants

The threat of new entrants for Laboratorios Farmaceuticos Rovi, S.A. is high due to the growing demand for pharmaceutical products and the ease of entry into the market.

Intensity Of Rivalry

The intensity of rivalry for Laboratorios Farmaceuticos Rovi, S.A. is high due to the presence of several established players in the pharmaceutical industry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 10.82%
Debt Cost 3.95%
Equity Weight 89.18%
Equity Cost 6.34%
WACC 6.08%
Leverage 12.13%

11. Quality Control: Laboratorios Farmaceuticos Rovi, S.A. passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Genmab

A-Score: 5.8/10

Value: 3.2

Growth: 9.7

Quality: 9.5

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
ALK-Abelló

A-Score: 5.0/10

Value: 0.2

Growth: 8.2

Quality: 7.8

Yield: 0.0

Momentum: 9.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Alkermes

A-Score: 5.0/10

Value: 4.9

Growth: 8.4

Quality: 8.9

Yield: 0.0

Momentum: 4.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Rovi

A-Score: 4.8/10

Value: 1.8

Growth: 7.7

Quality: 8.1

Yield: 2.5

Momentum: 3.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Camurus

A-Score: 4.7/10

Value: 0.2

Growth: 9.3

Quality: 9.1

Yield: 0.0

Momentum: 7.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Zealand Pharma

A-Score: 3.3/10

Value: 7.0

Growth: 2.2

Quality: 9.9

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

82.2$

Current Price

82.2$

Potential

-0.00%

Expected Cash-Flows